Wednesday, December 27, 2017

Two Papers about Adverse Outcome Pathways

Slice of Fig. 5 of Penny's paper (see main text).
Over the past year our group got involved in two projects where Adverse Outcome Pathways (AOPs) are used. These AOPs are risk assessment tools, but when linked to biological pathways they get a lot more interesting. the key events (KEs) in the AOPs can be linked to bioassays and thus biological processes. Earlier this year Marvin Martens (follow him on Twitter) started as PhD candidate to work on EU-ToxRisk and OpenRiskNet on exactly this integration. The first of these two projects got recently described in "Adverse outcome pathways: opportunities, limitations and open questions" (doi:10.1007/s00204-017-2045-3).

But at the end of eNanoMapper we collaborated with Penny Nymark and Roland Grafstr√∂m on bioassay measurements of biological responses to exposure of nanomaterials. "We" is particularly Freddie and Linda who worked with Penny to develop an approach to link AOPs with biological pathways, and the worked on this lung fibrosis pathway:

Penny's paper the describes this approach and this pathway was also recently published: "A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions"  (doi:10.1093/toxsci/kfx252).

BTW, this <iframe> embeds this pathway in the page using the JavaScript library pvjs by Anders Riutta from the Gladstone Institutes. You can click the genes to get identifiers for various databases. You can learn on this page on how to use this on your webpage or blog.